<DOC>
	<DOCNO>NCT02363452</DOCNO>
	<brief_summary>The purpose study determine treatment reverse transcriptase inhibitor return interferon signature observe patient AGS normal level .</brief_summary>
	<brief_title>Reverse Transcriptase Inhibitors AGS</brief_title>
	<detailed_description>AGS genetically heterogeneous disease result mutation one gene encode 3-prime repair exonuclease TREX1 ( AGS1 ) , three non-allelic component RNASEH2 endonuclease complex ( AGS2 , 3 4 ) , Sam domain HD domain contain protein ( SAMHD1 ; AGS5 ) function deoxynucleoside triphosphate triphosphohydrolase , double strand RNA edit enzyme ADAR1 , cytosolic dsRNA sensor IFIH1 . It hypothesize AGS1-6 involve limit accumulation intracellular nucleic acid specie , failure process result trigger innate immune response normally induced viral nucleic acid . That , absence AGS-related protein activity , endogenous nucleic acid accumulate sensed viral 'non-self ' , lead induction interferon ( IFN ) alpha mediate immune response production antibody self nucleic acid . AGS associate increased level interferon alpha cerebrospinal fluid ( CSF ) serum . Available data suggest AGS might treat ( particular ) reverse transcriptase inhibitor ( compound potentially disrupt exogenous retroviral endogenous retroelement cycling ) . No systematic approach treatment AGS explore . The investigator hypothesis reverse transcriptase inhibitor also inhibit reverse transcription endogenous retroelements deem responsible initiate tissue damage see AGS . Consequently , purpose investigator pilot study , would ideal assess effect therapy monitor reactive biomarker . This single centre , open , single arm , phase II study child AGS . This study design justify data available antiretroviral drug efficacy child AGS . Moreover , study first step phase III study drug efficacy . The investigator propose pilot clinical trial select reverse transcriptase inhibitor AGS patient , specific endpoint assess effect treatment disease-associated interferon signature . The investigator propose evaluate safety combination therapy comprise three nucleoside analog reverse-transcriptase inhibitor ( NRTIs ) zidovudine ( AZT ) , lamivudine ( 3TC ) , abacavir ( ABC ) patient AGS 52 week period treatment . The inclusion period 12 month . Patients participate biomedical trial another drug 18 month follow-up ( 12 month treatment period plus 6 month post treatment period ) . A total six visit ( include final visit ) schedule trial period 18 month ( M1 , M3 , M6 , M9 , M12 , M18 ) patient . Drugs dispense medication home , usual dos recommend HIV infection . Subjects dose accord French guideline . Dosing review study visit current weight , modify necessary accordance French dose guideline .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Nervous System Malformations</mesh_term>
	<mesh_term>Autoimmune Diseases Nervous System</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>A molecular diagnosis AGS i.e . biallelic know dominant mutation , pathogenicity assess use extensive mutation database / functional data , TREX1 , RNASEH2A , RNASEH2B , RNASEH2C SAMHD1 gene A predefined interferon signature ( consistently present , moderate high , least three occasion , period 6 month prior enrolment study ) Age ≥ 1 month &lt; 18 year ( either sex ) Patient beneficiary affiliate `` health insurance '' Written inform consent Preexisting disease , due AGS , would preclude use zidovudine , Lamivudine abacavir ( currently assess routine clinical HIVrelated practice ) HLA B5701 positive result , indicate great risk abacavir hypersensitivity reaction Patients abnormally low neutrophile count ( &lt; 0.75 x 109/l ) , abnormally low haemoglobin level ( &lt; 7.5 g/dl 4.65 mmol/l ) ( zidovudine contraindication ) Positive serology HIV , HBV Known history cirrhosis history clinically relevant hepatitis within last 6 month Moderate severe renal impairment Pregnancy , breastfeed Patient participate biomedical research drug</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Aicardi-Goutières syndrome</keyword>
	<keyword>Reverse transcriptase inhibitor</keyword>
	<keyword>open single study</keyword>
	<keyword>interferon signature</keyword>
</DOC>